AC Immune SA
ACIU
$2.79
$0.010.18%
NASDAQ
| 06/30/2026 | 12/31/2025 | 06/30/2025 | 03/31/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | 1,080.99% | -67.32% | 108.40% | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 1,080.99% | -67.32% | 108.40% | -- | -- |
| Cost of Revenue | -36.46% | -26.02% | 7.63% | 2.07% | 2.07% |
| Gross Profit | 130.49% | 22.82% | -3.42% | 4.27% | 4.27% |
| SG&A Expenses | -7.15% | 15.72% | -6.27% | -13.07% | -13.07% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -344.94% | -474.84% | 41.06% | 101.41% | 101.41% |
| Total Operating Expenses | -31.36% | -17.96% | 4.80% | -1.33% | -1.33% |
| Operating Income | 106.28% | 14.95% | -1.40% | 6.12% | 6.12% |
| Income Before Tax | 109.03% | -0.03% | -2.06% | -3.61% | -3.61% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 109.03% | -0.01% | -2.06% | -3.61% | -3.61% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 109.03% | -0.01% | -2.06% | -3.61% | -3.61% |
| EBIT | 106.28% | 14.95% | -1.40% | 6.12% | 6.12% |
| EBITDA | 107.88% | 15.25% | -1.33% | 6.05% | 6.05% |
| EPS Basic | 108.62% | 1.06% | -0.99% | -2.53% | -2.53% |
| Normalized Basic EPS | 108.65% | 0.98% | -0.95% | -2.57% | -2.57% |
| EPS Diluted | 108.62% | 2.68% | -0.99% | -2.53% | -2.53% |
| Normalized Diluted EPS | 108.65% | 0.98% | -0.95% | -2.57% | -2.57% |
| Average Basic Shares Outstanding | 4.59% | 1.08% | 1.09% | 1.03% | 1.03% |
| Average Diluted Shares Outstanding | 4.59% | 1.08% | 1.09% | 1.03% | 1.03% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |